is bpc-157 on fda 503a bulks list FDA's own advisory committee voted 8-6 Thursday. BPC-157, the compounding now, for ulcerative colitis. staff argued against it, laid out the data gaps, the whole case. Panel overruled them The FDA just dropped a

The FDA just dropped a 68 page PDF on if BPC 157 should be legal or not to compound. Their initial recommendation: DO NOT add BPC 157 to the 503A Bulks List. They're meeting this Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8 6 to recommend adding BPC 157 to the 503A Bulks List for use in compounding for A majority of FDA's Pharmacy Compounding Advisory Committee voted in favor of allowing bulk compounding of BPC 157 #PCAC #peptides FDA staff recommends against adding any of these 7 peptides to the 503A Bulks List: BPC 157 (free base acetate) KPV (free base acetate) TB 500 (free base acetate) MOTS c (free base acetate) BPC 157 PASSED! Gabriel Alizaidy, MD, MS I also agree with you, the FDA's data pitch was very disappointing For the compounding industry, this is a positive vote. It does not immediately make

SKU: 20991609221 · From lagence-mr.com